Browse studies

Find your next paid study

6 recruiting studies matching your filters

Distance-Based Exercise to Preserve Function and Prevent Disability

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and a…

Localized Malignant Solid NeoplasmAnal CancerBladder (Urothelial, Transitional Cell) Cancer+16 more

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07059884

Phase 1

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with…

Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more

Estimated

~$10 – $8,750

Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have…

Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more

Estimated

~$10 – $1,125

AstraZenecaNCT07124000

Phase 1

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of the IKS04 Regimen Targeting CA242

This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify…

Colorectal CancerGastro Esophageal Junctional CancerGastric Cancer (GC)+5 more

Estimated

~$10 – $8,750

Iksuda Therapeutics Ltd.NCT07738939

Phase 1

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibiti…

Bile Duct CancerGall Bladder CancerBreast Cancer+6 more

Estimated

~$10 – $6,250

University of FloridaNCT05000294

Observational

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-…

Small Bowel CancerColorectal CancerAppendiceal Cancer+5 more

Estimated

~$10 – $6,250

University of California, DavisNCT06101277